Francesca Morgan
Market Report
15:32, 15th September 2020

Bidstack (AIM:BIDS FOLLOW) shares rose 24.75% to 6.3p with exclusive partnership with Ubisoft 

The advertising group has signed an exclusive partnership agreement with Ubisoft, a leading video game company, to deliver native in-game advertising for video game, Hyper Scape. 

The partnership follows Bidstack's strategy to focus on working with leading video games developers and publishers to incorporate its proprietary technology into their games.   

"This deal shows the progress the business has made over the last two years,” said CEO, James Draper, adding, “The team at Ubisoft has become a close partner, and together we're excited to empower advertisers to run campaigns within the cross-platform battle royale Hyper Scape.” 

In a half-year results published last month, Draper said Bidstack has made material progress on the demand-side in its first half as it sees advertisers moving beyond initial test spends.    

Financially, the group posted revenues for 1H20 of £0.3m up from £0.03m for the period ended 30 June 2019 with £5.9m of cash after an oversubscribed £5.7m equity raise in June. 

Bidstack said the proceeds leave it in ‘a healthy cash position’ to pursue its business plans, which clearly include working exclusively with Ubisosft on HyperScape. 


Cerillion (AIM:CER FOLLOW)  shares rose 11.53% to 329p after biggest ever contract win 

The software solutions provider announced its largest ever contract win this morning in an agreement worth £11.2m with a major UK provider of enterprise connectivity solutions. 

The majority of income, including software licences and services, is expected to be recognised in the next 12 months, and the contract has an overall term of five years. 

The contract is to supply and implement its Enterprise BSS/OSS* Suite, the Company's pre-integrated end-to-end CRM and billing solution. It will be delivered in a private cloud to support the full 'lead-to-cash' process for a wide range of unified communications services. 

Louis Hall, CEO of Cerillion, said, "We are delighted to have been awarded this major contract, the biggest single win in Cerillion's history.” 

He added, “This is the latest demonstration of the ongoing momentum of the business and increasing recognition of the quality of our solutions." 

Pipehawk (AIM:PIP FOLLOW) shares rose 42.11% to 6.75p with new subsidiary contract 

The group’s wholly owned subsidiary, QM Systems Limited, was awarded a contract to provide a 'state of the art' complete manufacturing facility to Isoclad Limited. 

QM Systems will therefore manufacture specialist clad panels for its CustomClad service. 

The project, which is worth around £1.7m and will start immediately, is due for completion within the current financial year. 

Isoclad is one of the UK's largest independent composite panel manufacturers. The Customclad service was developed to meet the growing requirement for custom panels across the data, storage and modular build fields. 

"This is excellent news and demonstrates how the diverse nature of QM Systems's portfolio of partners and unique skill set has enabled it to navigate the difficult conditions experienced in light of the current COVID-19 crisis, and continues to provide innovation driven manufacturing solutions,” said Gordon Watt, Chairman of PipeHawk. 

SimplyBiz Group (AIM:SBIZ FOLLOW) shares rose 8.16% higher at 161p with strong trading 

In its half-year results, the group reported strong and resilient trading for the six months ended 30 June 2020 which the company said is demonstrative of “the robust nature” of the business.  

SimplyBiz said it had taken ‘strong and positive action in the first week of national lockdown to ensure it could fully support its customers and colleagues.  

While the Distribution Channels division was significantly impacted by the COVID-19 restrictions, with revenues reducing by 31% to £9.2m, Fintech and Research remained the resilient segments for the Company with revenues growing 77% year on year.  

The group therefore reported total revenue of £28.9m for the period, 1% lower than £29.1m recorded in the prior period.  

“The quality of our revenues, the resilience of our customers, and the benefits of a stronger digital delivery platform have enabled strong trading during challenging times,” said Matt Timmins, Joint CEO of The SimplyBiz Group.  

The board said it remains confident of the group’s strong trading and cash generation and expects that 2020 full year adjusted earnings per share shall be no less than 11.0p.  

Amryt Pharma (AIM:AMYT FOLLOW) shares rose 8.50% higher at  217p with positive opinion 

The biopharmaceutical group said the European Medicines Agency ("EMA") Committee for Orphan Medicinal Products ("COMP") has adopted a positive opinion for orphan designation for the use of its preclinical development, AP103, in Epidermolysis Bullosa ("EB"). 

AP103 is based on its gene-therapy platform technology and offers a potential treatment for patients with Dystrophic Epidermolysis Bullosa ("DEB"), a subset of EB. 

Orphan drug designation in the EU is granted by the European Commission within 30 days of a positive opinion being issued by the EMA COMP. The designation gives regulatory and financial incentives such as product market exclusivity for 10 years in the EU once approved. 

Amryt told investors this morning that it plans to submit an orphan drug designation request for AP103 to the US Food and Drug Administration ("FDA") ‘in the near future.’ 

AP103 is the first gene therapy product candidate based on our novel polymer-based topical gene-therapy delivery platform, which also has potential use for the treatment of other rare genetic diseases. Amryt intends to initiate AP103’s clinical development in 2022’s first half. 

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles